<DOC>
	<DOC>NCT01339676</DOC>
	<brief_summary>This is a multi-centre, double blind, randomised, placebo controlled, parallel group, phase 4 pilot study investigating colecalciferol (vitamin D3) as an add-on treatment to subcutaneously administered interferon-beta-1b in relapsing-remitting multiple sclerosis patients.</brief_summary>
	<brief_title>Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>age 18 to 55 years remittingrelapsing multiple sclerosis according to McDonald criteria who fulfill the reimbursement criteria for interferonbeta and have used interferonbeta1b for at least one month EDSS (expanded disability statsu scale) â‰¤ 5 no neutralising antibodies to INFB as measured by indirect MxA test prepared and considered to follow the protocol using appropriate contraceptive methods (women of childbearing potential) has given informed consent serum calcium &gt;2.6 mmol/L serum 25(OH)D2 (kalsidiol) &gt; 85 nmol/L presence of primary hyperparathyroidism (serum intact PTH, parathyroid hormone)&gt;65 ng/L) pregnancy or unwillingness to use contraception alcohol or drug abuse use of glucocorticoid treatment other than intravenous methylprednisolone for treatment of relapses current use of other immunomodulatory therapy than interferonbeta1b known allergy to cholecalciferol or arachis oil (peanuts) therapy with digitalis, calcitonin or active vitamin D3 analogues during the previous 12 months or multivitamins containing vitamin D during previous two weeks preceding study entry any condition predisposing to hypercalcaemia (such as any type of cancer) sarcoidosis nephrolithiasis or renal insufficiency, serum creatinine above 1.5 times the normal upper reference limit significant hypertension (Blood Pressure &lt;180/110 mmHg) hyperthyroidism, or hypothyroidism in the year before the study began a history of nephrolithiasis during the previous five years cardiac insufficiency or significant cardiac dysrhythmia unstable or advanced ischaemic heart disease has suffered a major depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MRI</keyword>
	<keyword>Randomised Trial</keyword>
	<keyword>Finland</keyword>
</DOC>